Evidence map›Paper›PMID 31791317›Full record

ArticleBMC complementary and alternative medicine2019

The mycelium of the Trametes versicolor (Turkey tail) mushroom and its fermented substrate each show potent and complementary immune activating properties in vitro.

Kathleen F Benson, Paul Stamets, Renee Davis, Regan Nally, Alex Taylor, Sonya Slater, Gitte S Jensen

Open access · goldAbstract read
In one paragraph

Article in BMC complementary and alternative medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Investigation ofVeterinary sciences · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. COVID-19 and Cancer Diseases-The Potential ofInternational journal of molecular sciences · 2023
    Review
  14. The Health and Clinical Benefits of Medicinal Fungi.Advances in biochemical engineering/biotechnology · 2023
    Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Mushrooms as future generation healthy foods.Frontiers in nutrition · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kathleen F BensonNIS Labs, 1437 Esplanade, Klamath Falls, Oregon, 97601, USA.
Paul StametsFungi Perfecti, Postal Box 7634, Olympia, Washington, 98507, USA.
Renee DavisFungi Perfecti, Postal Box 7634, Olympia, Washington, 98507, USA.
Regan NallyFungi Perfecti, Postal Box 7634, Olympia, Washington, 98507, USA.
Alex TaylorFungi Perfecti, Postal Box 7634, Olympia, Washington, 98507, USA.
Sonya SlaterFungi Perfecti, Postal Box 7634, Olympia, Washington, 98507, USA.
Gitte S JensenNIS Labs, 1437 Esplanade, Klamath Falls, Oregon, 97601, USA. gitte@nislabs.com.ORCID http://orcid.org/0000-0002-9497-1750
Bavarian Nordic (United States) · USKlamath Community College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe medicinal mushroom Trametes versicolor (Tv, Turkey Tail) is often prepared for consumption as a powder from the fungal mycelium and the fermented substrate on which it grew. The goal for this study was to evaluate the immune-modulating properties of the mycelium versus the fermented substrate, to document whether an important part of the immune-activating effects resides in the metabolically fermented substrate.

methodsTv mycelium was cultured on rice flour. The mycelium and the fermented substrate were mechanically separated, dried, and milled. The initial substrate served as a control. Aqueous fractions were extracted and passed through 0.22-μm filters. The remaining solids were passed through homogenization spin columns without filtration. The aqueous and solid fractions of the initial substrate (IS), the fermented substrate (FS), and the Trametes versicolor mycelium (TvM) were tested for immune-activating and modulating activities on human peripheral blood mononuclear cell cultures, to examine expression of the CD69 activation marker on lymphocytes versus monocytes, and on the T, NKT, and NK lymphocyte subsets. Culture supernatants were tested for cytokines using Luminex arrays.

resultsBoth aqueous and solid fractions of TvM triggered robust induction of CD69 on lymphocytes and monocytes, whereas FS only triggered minor induction of CD69, and IS had no activating effect. The aqueous extract of TvM had stronger activating effects than the solid fraction. In contrast, the solid fraction of IS triggered a reduction in CD69, below levels on untreated cells. Both aqueous and solid fractions of FS triggered large and dose-dependent increases in immune-activating pro-inflammatory cytokines (IL-2, IL-6), anti-inflammatory cytokines Interleukin-1 receptor antagonist (IL-1ra) and Interleukin-10 (IL-10), anti-viral cytokines interferon-gamma (IFN-γ) and Macrophage Inflammatory Protein-alpha (MIP-1α), as well as Granulocyte-Colony Stimulating Factor (G-CSF) and Interleukin-8 (IL-8). TvM triggered more modest cytokine increases. The aqueous extract of IS showed no effects, whereas the solid fraction showed modest effects on induction of cytokines and growth factors.

conclusionThe results demonstrated that the immune-activating bioactivity of a mycelial-based medicinal mushroom preparation is a combination of the mycelium itself (including insoluble beta-glucans, and also water-soluble components), and the highly bioactive, metabolically fermented substrate, not present in the initial substrate.

Indexed as

Antigens, CDAntigens, Differentiation, T-LymphocyteAnti-Inflammatory AgentsBiological ProductsCD69 AntigensCells, CulturedCytokinesFermentationHumansImmunologic FactorsLectins, C-TypeLeukocytes, MononuclearMyceliumOryzaTrametesAntigens, CDAntigens, Differentiation, T-LymphocyteAnti-Inflammatory AgentsBiological ProductsCD69 AntigensCytokinesImmunologic FactorsLectins, C-TypeAnti-inflammatoryCD69CytokinesImmune modulation

Identifiers

PMID31791317
PMCPMC6889544
OpenAlexW2992324802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.